Related Experiment Video

Updated: Apr 20, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

11.9K

Association of natriuretic peptide polymorphisms with left ventricular dysfunction in southern Han Chinese coronary

Zhijun Wu1, Min Xu1, Haihui Sheng2

  • 1Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China.

International Journal of Clinical and Experimental Pathology
|November 18, 2014
PubMed

Insights

Certain natriuretic peptide gene polymorphisms (NPPA-NPPB) are linked to a lower risk of left ventricular dysfunction (LVD) in coronary artery disease (CAD) patients with hyperlipidemia.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetics of Heart Failure

Background:

  • Left ventricular dysfunction (LVD) is a complication of myocardial ischemia and coronary artery disease (CAD).
  • The natriuretic peptide system plays a compensatory role in LVD and heart failure.
  • Investigating genetic factors influencing LVD risk in CAD patients is crucial.

Purpose of the Study:

  • To examine the association between natriuretic peptide gene polymorphisms and the risk of LVD in patients with CAD.
  • To identify specific polymorphisms within the NPPA-NPPB locus that may influence LVD development.

Main Methods:

  • Recruited 747 Southern Han Chinese patients with confirmed CAD.
  • Categorized patients into LVD (LVEF ≤45%) and preserved LVEF groups, matched for age and gender.
  • Utilized Taqman assays to analyze five polymorphisms in the NPPA-NPPB locus (rs5065, rs5063, rs632793, rs198388, rs198389).

Main Results:

  • No significant association was found between single-locus polymorphisms and LVD risk overall.
  • Subgroup analysis in patients with hyperlipidemia (HLP) revealed three polymorphisms (rs632793, rs198388, rs198389) associated with reduced LVD risk.
  • Multifactor dimensionality reduction analysis did not detect significant gene-gene interactions.

Conclusions:

  • Specific NPPA-NPPB polymorphisms (rs632793, rs198388, rs198389) are associated with a decreased risk of LVD.
  • This protective association was observed in CAD patients with hyperlipidemia.
  • These findings highlight potential genetic markers for LVD risk stratification in specific CAD patient subgroups.
Abstract

Keywords:
Left ventricular dysfunctioncoronary artery diseaseheart failurenatriuretic peptidepolymorphism

More Related Videos

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart08:22

Isolation of Endocardial and Coronary Endothelial Cells from the Ventricular Free Wall of the Rat Heart

Published on: April 15, 2020

19.8K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
789
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74